A
Age factors, 13–14
American Urologic Association Symptom score (AUASS), 112, 116
Antidiuretic pharmacotherapy
arginine vasopressin (AVP), 136–138
desmopressin
Noctopus trials, 138–141
structure and mechanism of action, 137–138
USA and Canada trial, 141–142
hyponatremia, 142
Antidiuretic therapy, 7
Antimuscarinics, 128, 133
Antimuscarinic therapy, overactive bladder, 128–130
Arginine vasopressin (AVP), 136–138

B
Benign prostatic hyperplasia (BPH), 77, 89–91, 95, 96, 115–124
BMI, 29–30

C
Cardiovascular diseases, 19–21
Combined therapy, 132
Comorbid disease, 151, 158
Coronary disease, 91–92

D
Depression, 90–91
Desmopressin, 127
Noctopus trials, 138–141
structure and mechanism of action, 137–138
USA and Canada trial, 141–142
Detrusor overactivity, 111, 112
Diabetes, 94
Diabetes insipidus, 4
Diary-based population analysis
frequency volume charts (FVC), 60–61
Krimpen study protocol
baseline round, 61–65
cross-sectional data, 66–70
follow-up rounds, 65
longitudinal data, 70–74

E
Elderly
causes, 148, 149
diary-based population analysis
(see Diary-based population analysis)
family and caregiver burden, 150
healthcare costs, 150
morbidity, 151
mortality, 152
quality-of-life impact, 148–149
sleep disturbance, 150
treatment issues, 152–153
Ethnicity, 15

F
Falls, 48, 89, 151
Family and caregiver burden, 150
Female reproductive/gynecologic factors, 27–28
Fesoterodine, 129, 130
Finasteride, 161
Finnish National Nocturia and Overactive Bladder (FINNO), 79, 86–89, 91–95, 97, 98
Fluid volume disturbance, 24–26
Fractures, 48, 89
Frequency volume charts (FVC), 60–61

G
Gender factors, 15
Global polyuria, 4–6, 24–25
Gravidity, 97–98

H
Healthcare costs, 150
Health economics research, 166
Herbal/dietary supplements
difficulties in evaluation, 159–160
efficacy, 160–161
finasteride, 161
Permixon®, 161–162
plant extracts/supplements, 158
product variability, 160
Saw palmetto berry (SPB) mechanisms of action, 159
Saw palmetto for treatment of enlarged prostates (STEP) trial, 162
side effects monitoring, 163
tamsulosin, 161–162
Hormone therapy, 98
Hours of uninterrupted sleep (HUS), 120, 123
Hypertension, 91–92
Hyponatremia, 142

I
Incidence, 81–85
International Consultation on Incontinence
Modular Questionnaire–Nocturia Quality of Life questionnaire, 86
International Consultation on Incontinence
Nocturia Quality of Life (NQOL), 118–120, 123
International Consultation on Incontinence Questionnaire for Nocturia (ICIQ-N), 5
International Prostate Symptom Score (IPSS), 60, 61, 64, 67, 73, 74

K
Krimpen study protocol
baseline round, 61–65
cross-sectional data, 66–70
follow-up rounds, 65
longitudinal data
nocturia prevalence, 70
nocturnal polyuria prevalence, 70–74

L
Latchkey syndrome, 113
Lifestyle and behavioral factors, 28–29, 96
Lifestyle changes, 157–158
Lower urinary tract factors, 16–19
Lower urinary tract pharmacotherapy
antimuscarinic therapy, overactive bladder, 128–130
combined therapy, 132
obstructive BPH management therapy, 130–132
others, 132–133
Lower urinary tract symptoms (LUTS), 77, 79, 85, 89, 90, 95–97, 115, 116, 120–124, 147, 149, 150

M
Maximum voided volume (MVV), 2
Medical conditions
BMI and obesity, 29–30
cardiovascular diseases, 19–21
conditions
benign prostatic hyperplasia, 89–90
depression, 90–91
hypertension and coronary disease, 91–92
neurological diseases, 93
nocturnal polyuria, 93–94
obesity and diabetes, 94
overactive bladder and detrusor overactivity, 94–95
prostate cancer, 95–96
demographic factors
age, 13–14
ethnic or cultural groups, 15
gender, 15
female reproductive/gynecologic factors, 27–28
fluid intake, 30–31
fluid volume disturbance, 24–26
lifestyle and behavioral factors, 28–29, 96
lower urinary tract factors, 16–19
physical activity, 31–32
pulmonary, 21–22
race/ethnicity and socioeconomic status, 96–97
reproductive factors in women
gravidity/pregnancy, parity and post-partum period, 97–98
Menopause and hormone therapy, 98
pelvic surgery, 98
sleep-related factors, 22–24
smoking, 31
socioeconomic factors, 26–27
Menopause, 98
Micturition, 110
Minimally invasive surgical therapies (MIST), 122
Mixed nocturia, 4
Morbidity, 37–38, 151
Mortality, 37–38, 89, 152

N
Near nocturia, 165
Neurological diseases, 93
Nighttime falls. See Falls
Noctopus trials, 138–141
Nocturia
antidiuretic pharmacotherapy (see Antidiuretic pharmacotherapy)
consequences, 6
definition, 1–2, 111–112
diary-based classification
decreased nocturnal bladder capacity, 3–4
global polyuria, 4–6
vs. medical conditions, 3
mixed nocturia, 4
nocturnal polyuria (NP), 2–3
nocturnal urine volume (NUV), 2
diary-based population analysis (see Diary-based population analysis)
frequency–volume charts, 165
future investigation, 165–166
impact
bother and quality of life, 85–88
falls, fractures and mortality, 89
lower urinary tract pharmacotherapy (see Lower urinary tract pharmacotherapy)
older persons (see Elderly)
vs. overactive bladder, 112–113
predictors and risk factors (see Medical conditions)
sleep deprivation, 6–7 (see also Sleep; Sleep apnea; Sleep disorders)
therapy, 7–8
treatment with alternative therapies
lifestyle changes, 157–158
supplements, 158–162 (see also Herbal/dietary supplements)
Nocturia Nocturnal Enuresis and Sleep-interruption Questionnaire (NNES-Q), 148
Nocturia Quality-of-Life (N-QOL), 5
Nocturnal polyuria (NP), 2–3, 62, 65, 68, 72, 93–94, 136–144
Nocturnal urine volume (NUV), 2, 25–26

O
Obesity, 29–30, 94
Obstructive BPH management therapy, 130–132
Obstructive sleep apnea (OSA), 161.
See also Sleep apnea
Older persons. See Elderly
Overactive bladder (OAB)
antidiuretic pharmacotherapy, 136, 137, 140–143
antimuscarinic therapy, 128–130
definition, 110–111
and detrusor overactivity, 94–95
future research, 113
vs. nocturia, 112–113

P
Parity, 97–98
Pelvic surgery, 98
Permixon®, 160–162
Physical activity, 31–32
Pittsburgh Sleep Quality Index (PSQI), 5
Plant extracts/supplements, 158
Poor sleep, 48, 52
Post-partum period, 97–98
Predictors and risk factors. See Medical conditions
Pregnancy, 97–98
Prescribing cascade, 152
Prevalence, 79–81
Prostate cancer, 95–96
treatment (see Surgical treatment)
Pulmonary diseases, 21–22

Q
Quality-of-life (QoL), 85–88, 148–149

R
Race/ethnicity and socioeconomic status, 96–97
Radical prostatectomy (RP), 121
Reproductive factors in women
gravidity/pregnancy, parity and post-partum period, 97–98
menopause and hormone therapy, 98
pelvic surgery, 98
Risk factors. See Medical conditions
S
Saw palmetto berry (SPB) mechanisms of action, 159
Saw palmetto for treatment of enlarged prostates (STEP) trial, 162, 163
Sleep
continuity, 46–48
disturbance, 52, 150
duration
in people with nocturia versus controls, 42
quantity, 39–42
efficiency, 43, 46
stages, 42
SWS, 43–45
Sleep apnea
acute and intermediary mechanisms, 50
clinical syndrome, 49
diagnosis and treatment, 50–52
nocturia-related sleep deprivation, 52–53
Sleep disorders
day time functioning and quality of life (QoL), 38–39
falls and fractures, 48
medical conditions, 22–24
morbidity and mortality, 37–38
Sleep-related factors, 22–24
Smoking, 31
Socioeconomic factors, 26–27
Solifenacin, 128, 129
Surgical treatment
in men with BPH and nocturia
BPH impact index, 116, 118
HUS, 120
IPSS/AUASS, 116, 117
NQOL, 118–120
therapy
effect of PVP laser, 122–123
minimally invasive surgical therapies (MIST), 122
radical prostatectomy (RP), 121
regression analysis and NQOL, 123
transurethral resection of the prostate (TURP), 121–122
T
Tamsulosin, 161–162
Tolterodine, 129, 130, 132
Transurethral resection prostate (TURP), 7, 115, 121–123
Trospium chloride, 129
U
Uncontrolled diabetes mellitus, 4
Urgency, 110, 112, 113
Urgency Perception Score, 110–111
USA and Canada trial, 141–142
W
Water deprivation testing, 5